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Abstract 
Melanoma was again a focus of attention at the 2015 American Society of Clinical Oncology (ASCO) Annual Meet-
ing, in particular the use of combination treatment strategies involving immunotherapies and/or targeted agents. 
New data on targeted therapies confirmed previous findings, with combined BRAF inhibitor (vemurafenib) plus MEK 
inhibitor (cobimetinib) improving progression-free survival (PFS) compared to vemurafenib monotherapy in patients 
with BRAFV600 mutation-positive tumors (CoBRIM trial). Positive results were also seen with combined dabrafenib 
and trametinib in patients with BRAF V600E/K metastatic melanoma and encorafenib plus binimetinib in BRAFV600-
mutant cutaneous melanoma. Even more interesting news centered on the use of combination immunotherapy, in 
particular the randomized, double-blind CheckMate 067 study in which median PFS with nivolumab plus ipilimumab 
was 11.5 months, compared to 2.9 months with ipilimumab alone (HR 0.42) and 6.9 months with nivolumab alone 
(HR 0.57). Of interest, in patients with ≥5% PD-L1 expression, median PFS was 14 months with the combination or 
with nivolumab alone compared with 3.9 months in the ipilimumab group, while in the PD-L1 negative cohort, the 
combination remained superior to both monotherapies. Given that combination therapy was accompanied by a high 
occurrence of side-effects, this raises the suggestion that combination therapy might be reserved for PD-L1 nega-
tive patients only, with PD-L1 positive patients achieving the same benefit from nivolumab monotherapy. However, 
overall survival data are awaited and the equivalence of single agent to the combination remains unconvincing. Inter-
esting data were also reported on the combination of T-VEC (talimogene laherparepvec) with ipilimumab, and the 
anti-PD-1 agent MEDI4736 (durvolumab) combined with dabrafenib plus trametinib. Emerging data also suggested 
that predictive markers based on immunoprofiling and mismatch repair deficiency may be of clinical use. In conclu-
sion, the use of combination approaches to treat patients with melanoma, as well as other cancers, is no longer a just 
a wish for the future but is today a clinical reality with a rapidly growing evidence-base. Moreover, the most exciting 
consideration is that this is far from the end of the story, but rather a fantastic introduction.
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As in recent years, melanoma was a focus of attention at 
the 2015 American Society of Clinical Oncology (ASCO) 
Annual Meeting. If a single word could sum up this years’ 
melanoma news from ASCO, then “combination” would 
surely be the most appropriate.
New data were reported on targeted therapies, con-
firming the excellent results previously reported [1, 
2]. An update on the CoBRIM trial of combined BRAF 
inhibitor (vemurafenib) plus MEK inhibitor (cobimetinib) 
in patients with BRAFV600 mutation-positive tumors 
confirmed its superior impact on progression-free 
survival (PFS) compared to vemurafenib monotherapy 
[12.3 vs 7.2 months; hazard ratio (HR) 0.58 (0.46–0.72)]. 
As part of this study, an interesting biomarker analy-
sis that attempted to link clinical response with baseline 
oncogenic mutations found no correlation between out-
come and either RAS/RAF pathway mutations or tyros-
ine kinase receptor mutations (RTK) [3]. An update on 
overall survival (OS) from the Combi-D study of com-
bined dabrafenib plus trametinib in patients with BRAF 
V600E/K metastatic melanoma was also reported [4]. 
Patients treated with the combination of dabrafenib and 
trametinib achieved a median OS of 25.1  months with 
51% of patients still alive at 2 years, These findings con-
firmed results reported from the phase I–II study in 2014 
[5]. Finally, data from a phase Ib/II open-label study of 
patients with BRAFV600-mutant cutaneous melanoma 
treated with the newer combination of encorafenib plus 
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binimetinib showed an overall response rate (ORR) 
of 74.5% and a disease control rate (DCR) of 96.4%. Of 
interest, in the cohort receiving a dosage regimen of 
encorafenib 400/450 mg and binimetinib 45 mg, the ORR 
was 77.5% and the DCR was 100%. The combination was 
also well tolerated, with no grade 3–4 pyrexia or skin tox-
icity events reported [6]. Data from these three studies 
are summarized in Table 1.
Of even more interest were new data on combination 
immunotherapy, in particular the randomized, double-
blind phase III CheckMate 067 study that compared 
the combination of nivolumab plus ipilimumab with 
nivolumab and ipilimumab monotherapies [7]. This study 
enrolled 945 treatment-naïve patients with advanced dis-
ease who were stratified according to PD-L1 expression, 
BRAF mutation and disease stage. The study was pow-
ered to examine differences in PFS and OS for nivolumab 
or nivolumab plus ipilimumab each versus ipilimumab. 
PFS data were reported with the combination having 
a median PFS of 11.5 vs 2.9  months with ipilimumab 
[HR 0.42 (0.31–0.57)] and 6.9  months with nivolumab 
[HR 0.57 (0.43–0.76)]. An exploratory analysis showed 
the combination median PFS to be superior to that of 
nivolumab monotherapy [HR 0.74 (0.60–0.92)]. In addi-
tion, ORR was 57.6% for the combination, 43.7% with 
nivolumab and 19% with ipilimumab. PFS data stratified 
by PD-L1 status were especially interesting: with a cut-off 
of ≥5% for positive PD-L1 expression, median PFS was 
14 months for patients treated with either the combina-
tion or nivolumab alone compared with 3.9  months in 
the ipilimumab group. In the PD-L1 negative cohort, the 
combination confirmed its superiority to both monother-
apies with a PFS of 11.2 vs 5.3 months in the nivolumab 
group and 2.8 months in the ipilimumab group. However, 
we should be cautious in interpreting these data for sev-
eral reasons. Firstly, OS data are still awaited, with OS 
being the best endpoint for immunotherapy. Addition-
ally, in the PD-L1 positive group and in contrast to PFS, 
ORR was superior with the combination compared to 
nivolumab monotherapy (72.1 vs 57.5%). Finally, the per-
centage of patients with positive PD-L1 expression was 
only 21.7%, −25.3% which is the lowest observed across 
different studies (Table 2). Even with this stringent cut-off 
which excluded around two-thirds of responding patients 
and greatly enriched the cohort with those patients most 
likely to benefit from nivolumab, the equivalence of sin-
gle agent to the combination remained unconvincing.
An important consideration is that the improved PFS 
and ORR achieved with the combination was accompa-
nied by a high occurrence of side-effects: 55% of patients 
receiving the combination had grade 3–4 events and 
36.4% prematurely discontinued treatment because of 
its toxicity. However, over two-thirds (67.5%) of patients 
who discontinued treatment due to toxicities contin-
ued to respond. These data are consistent with those 
observed in another study of combined nivolumab and 
ipilimumab therapy (CheckMate 069), in which 54% of 
patients had grade 3–4 adverse events, leading to treat-
ment discontinuation in 38%; 68% of these continuing 
to respond despite the cessation of treatment [8]. One 
important characteristic of the immuno-related toxicity 
associated with the combination was the involvement of 
more than one organ, which is rare with monotherapy. 
However, new safety signals were not reported for the 
combination, with adverse events affecting the same 
organs as typically seen with monotherapy (i.e. the skin, 
gastrointestinal tract, liver, endocrine system, lungs). 
Moreover, these toxicities were manageable using the 
established algorithm for the treatment of the immuno-
related adverse events. Importantly, even in this large 
multi-national study in which many investigators had 
not previously used the combination regimen, there were 
no treatment-related deaths. It should also be noted that 
these side effects are primarily related to ipilimumab and 
similar levels of side effects were seen in studies using a 
high dose of ipilimumab, e.g. the phase III study of first-
line combined dacarbazine plus ipilimumab 10  mg/kg 
(50% grade 3–4 AEs) [9] and in the EORTC adjuvant trial 
with high-dosage ipilimumab (40.5%) [10].
This high-grade toxicity seen with combined nivolumab 
and ipilimumab together with the results based on 
PD-L1 expression has generated the possibility of using 
the combination in PD-L1 negative patients only, while 
PD-L1 positive patients might receive nivolumab mono-
therapy, since this may have a similar impact on PFS with 
less toxicity. However, as well as taking into account ear-
lier comments on the need to interpret these data with 
caution, the kinetics of action of the combination and 
Table 1 Comparison of CR, ORR, PFS, DoR, and OS among the different BRAF and MEK inhibitors combination
CR complete responses, HR hazard ratio, mDoR median duration of response, mOS median overall survival, mPFS median progression-free survival, ORR overall response rate.
BRAFi/MEKi combination Study CR (%) ORR (%) mPFS (HR) mDoR mOS (HR)
Dabrafenib + trametinib Phase III 13 69 11.0 (0.67) 12.9 25.1 (0.71)
Vemurafenib + cobimetinib Phase III 15.8 69.6 12.2 (0.58) 12.9 –
Encorafenib + binimetinib Phase I 12.7 74.5 11.3 – –
Page 3 of 5Ascierto et al. J Transl Med  (2015) 13:213 
nivolumab alone should also be considered (Figure  1). 
In comparing data from the phase I trials of nivolumab 
monotherapy with combined therapy, it is clear that 
the combination results in an earlier, deeper and more 
durable response [11, 12]. Moreover, some evidence has 
even shown a rapid effect of the combination (similar to 
targeted agents) in patients with bulky disease [13]. As 
such, assuming the OS data correlates with the ORR data, 
the combination of nivolumab plus ipilimumab should 
be considered as the new standard, with the caveat that 
anti-PD-1 therapy alone may be a valid option in patients 
where toxicity could be a concern, irrespective of PDL1 
status.
Another combined immunotherapeutic approach 
was the combination of T-VEC (talimogene laher-
parepvec), an oncolytic virus which includes a gene 
that encodes for GM-CSF, with ipilimumab [14]. These 
were an update of data presented at ASCO in 2014 
and, in the 18 patients enrolled to date, ORR was 56% 
and median (PFS) was 10.6  months. Median OS was 
not reached; 12- and 18-month survival were 72.2 and 
67%.
That targeted therapy has an important effect on the 
immune system is well known and the possibility of com-
bining a BRAF or MEK inhibitor with immunotherapy is 
an interesting approach. However, phase I data showed 
that combined vemurafenib and ipilimumab increases 
Table 2 PD-L1 as  a potential biomarker: % of  PD-L1 posi-
tive patients in different clinical trials




Ca209-067 ipilimumab/nivolumab arm [7] 21.7
Ca209-067 nivolumab monotherapy arm [7] 25.3
Keynote 006 pembro every 2 weeks [23] 80.6
Keynote 006 pembro every 3 weeks [23] 79.8
Keynote 002 [24] 69
Keynote 001 [25] 77
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Figure 1 Changes in target lesions: comparison between nivolumab alone (a) [11] and in combination with ipilimumab (b) [12]. In the phase I 
studies, the combo ipilimumab/nivolumab showed more rapid and durable changes in target lesions.
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liver toxicity (although this was not reported with dab-
rafenib plus ipilimumab) [15], while the triple combi-
nation of ipilimumab plus dabrafenib and trametinib 
has reported to increase the risk of bowel perforation. 
The development of anti-PD-1/PD-L1 agents which 
are more potent and less toxic than ipilimumab means 
the possibility of a combined approach with a BRAF or 
MEK inhibitor is more realistic. An interesting phase I 
study reported data on the combination of the anti-PD-
L1 antibody, MEDI4736 (durvolumab) with dabrafenib 
plus trametinib in patients with stage IIIc/IV melanoma 
[16]. Patients were enrolled by BRAF status into three 
different cohorts; BRAF-mutant patients received the 
triple combination and BRAF wild-type (WT) patients 
received durvolumab plus trametinib or sequential 
trametinib then durvolumab. Treatment with the tri-
ple combination resulted in an ORR of 69%, and DCR 
of 100%. In the BRAF WT cohorts, ORR was 21% and 
DCR was 79% in the combination group, while in the 
sequential group ORR was 13%, and DCR was 80%; how-
ever, data for the sequential group data could be affected 
by the short-term follow up. Most importantly, these 
combinations had a manageable safety profile. Despite 
these promising results, longer follow-up will be nec-
essary to determine the contribution of durvolumab 
to the impressive activity seen with the triple drug 
combination.
Finally, emerging data have suggested that predic-
tive markers based on immunoprofiling and mis-
match repair deficiency may be more meaningful than 
PD-L1. The interferon-γ signature 10 gene (related 
to inflammation) seemed to correlate with a better 
outcome in patients receiving the anti-PD-1 agent, 
pembrolizumab, both in terms of PFS and OS [17]. 
Similarly, although not in melanoma patients, data 
from a phase I study of patients with renal cell cancer 
reported that baseline upregulation of genes known to 
be upregulated by ipilimumab in melanoma, together 
with other immunorelated genes, was strongly corre-
lated with the outcome [18]. Another important find-
ing was the strong correlation between deficiency in 
the mismatch repair and the response to immunother-
apy that was evidenced in colorectal and other solid 
cancers and is likely to be a major focus of interest in 
the future [19].
In conclusion, the use of combination approaches to 
treat patients with melanoma, as well as other cancers, 
are no longer a just a wish for the future [20] but are 
today a clinical reality with a rapidly growing evidence-
base. Moreover, the most exciting consideration is that 
this is far from the end of the story, but rather a fantastic 
introduction.
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